GenesysCapital_Logo
  • About
  • Team
  • Portfolio
  • News
  • LP Login
LP Login
Left arrow Icon
Back to News

Inversago: Origin to $1.4 Billion USD

10 Aug 2023

This remarkable 5 year journey from $7M Series A investment to $1.4B acquisition is a story of Canadian entrepreneurs, innovation, and early catalysis by insightful investors and company builders.

View Full Article

Latest

Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares

06 December 2024

Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy

02 December 2024

Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025

04 November 2024

All Articles

December 6, 2024

Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares

Read More
December 2, 2024

Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy

Read More
November 4, 2024

Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025

Read More
October 31, 2024

Feldan Therapeutics announces the treatment of the first patient in the phase 1/2a clinical trial of its candidate fld-103, against Basal Cell Carcinoma

Read More
See All
About
Team
Portfolio
News
Contact
GenesysCapital_Logo
123 Front Street West, Suite 1503
Toronto ON M5J 2M2
info@genesyscapital.com
Follow us on LinkedIn
Privacy Policy
© 2025 Genesys Capital. All rights reserved.